Mixed views on Grattan Institute report on drug price cuts impact in Australia

3 December 2013
drugs_pills_tablets_big

The Grattan Institute has published an updated report on Australia’s drug pricing, which has been applauded by Health Minister Peter Dutton, but not by the generics sector.

Highlighting the 50.06% price cuts that were the result of price disclosure rules introduced in 2007 by the then Howard government, Mr Dutton said this has so far saved the Pharmaceutical Benefits Scheme (PBS) A$5 billion ($4.57 billion).

The Grattan report says the government’s purchasing policy needs to be much tougher on manufacturers and much fairer for consumers. It is not just a matter of saving money: nearly one in 10 Australians doesn’t take medicines a doctor prescribes because of cost. For six of the seven drugs with price cuts today, benchmarking would save patients nearly A$20 more for each box of pills, on average.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics